Executive record

Oren Gilad, Ph.D.

President, Chief Executive Officer and Director at Aprea Therapeutics, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:oren-gilad-ph-dVersion: public-0As of: 2026-09-29

Not yet claimed8 published Claims3 sources
  • Executive
  • Director

Key Claims

Biography

Served as CEO since July 2022 and President since May 2022. Previously President and CEO of Atrin Pharmaceuticals, leading its transaction with Aprea. Brings extensive drug development experience across multiple phases and authored high-impact scientific publications on the ATR pathway in cancer development.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. Current · dates not publishedPresident and Chief Executive Officer · Aprea Therapeutics, Inc.
  2. 2026 to end not publishedExecutive title: President and Chief Executive Officer · Organization not publishedAPRE 10-K executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Open source

    sec def 14a · Source published: Apr 30, 2026 · Retrieved: Sep 6, 2026

    Supports 2 claims
    • Professional Role: President, Chief Executive Officer and Director at Aprea Therapeutics, Inc. · Claim reviewed: Sep 6, 2026
    • Professional Role: President and Chief Executive Officer at Aprea Therapeutics, Inc. · Claim reviewed: Sep 6, 2026

  2. APRE 10-K executive officers

    sec filing · Source published: Mar 16, 2026 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at Aprea Therapeutics, Inc. · Claim reviewed: May 15, 2026
    • Executive title: Executive title: President and Chief Executive Officer · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  3. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Aprea Therapeutics, Inc. · Claim reviewed: Sep 6, 2026